Back to News
Market Impact: 0.15
Mineralys Reports Phase 2 Lorundrostat Data In Chronic Kidney Disease
Source: Nasdaq
Healthcare & Biotech
Mineralys Therapeutics announced that full results from its Phase 2 Explore-CKD trial of investigational lorundrostat were published in Kidney International. The available article text says the trial evaluated the drug in patients with uncontrolled high blood pressure and chronic kidney disease, but provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
MLYS0.60
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Needham initiates Clover Health stock with buy on cohort economics
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace